Analyzing...
Loading company...
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka and currently employs 2,731 full-time employees. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The firm's product range includes oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,539 Cr revenue.
COGS 29.9%, employees 21.8%.
“have reported the highest quarterly revenue of $4.”
“growth of 28% year on year”
“also reported our highest share of quarterly EBITDA at 115 crores as compared to 82 crore in '25, reflecting a robust growth of 41%.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 9.4%▼ | 10.3% |
| ROCE | 12.4%▼ | 13.7% |
| Net Margin | 15.7%▲ | 7.6% |
| EBITDA Margin | 30.6%▲ | 15.4% |
| Debt To Equity | 0.25x▲ | 0.15x |
| Rev Growth 3yr | 13.2%▲ | 10.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,538 Cr +19.6% | ₹1,286 Cr +11.7% | ₹1,152 Cr +9.7% | ₹1,050 Cr -8.3% | ₹1,146 Cr +27.1% | ₹901 Cr -0.7% | ₹908 Cr +23.8% | ₹733 Cr |
| Other Income | ₹11 Cr -54.1% | ₹23 Cr +183.4% | ₹8 Cr -53.0% | ₹17 Cr +22.1% | ₹14 Cr -52.7% | ₹30 Cr +77.9% | ₹17 Cr +23.3% | ₹14 Cr |
| Total Income | ₹1,549 Cr +18.3% | ₹1,310 Cr +12.9% | ₹1,160 Cr +8.6% | ₹1,068 Cr -8.0% | ₹1,160 Cr +24.5% | ₹931 Cr +0.7% | ₹925 Cr +23.8% | ₹747 Cr |
| COGS | ₹460 Cr +12.2% | ₹410 Cr +0.7% | ₹408 Cr -2.0% | ₹416 Cr +8.5% | ₹383 Cr +41.5% | ₹271 Cr -2.5% | ₹278 Cr +8.2% | ₹257 Cr |
| ₹1,283 Cr +10.8% | ₹1,158 Cr +4.6% | ₹1,107 Cr +0.4% | ₹1,102 Cr +3.7% | ₹1,063 Cr +33.6% | ₹795 Cr +8.0% | ₹736 Cr +18.2% | ₹623 Cr | |
| Profit Before Tax | ₹297 Cr +139.9% | ₹124 Cr +109.1% | ₹59 Cr ↑ Recovery | (₹34 Cr) ↓ Decline | ₹102 Cr -47.6% | ₹195 Cr +3.7% | ₹188 Cr +30.9% | ₹144 Cr |
| Exceptional Items | ₹30 Cr ↑ Recovery | (₹28 Cr) ↓ Decline | ₹6 Cr | ₹0.00 Cr -100.0% | ₹5 Cr -91.3% | ₹59 Cr ↑ Recovery | (₹0.35 Cr) ↓ Decline | ₹20 Cr |
| ₹52 Cr +18.1% | ₹44 Cr +96.7% | ₹22 Cr ↑ Recovery | (₹7 Cr) ↓ Decline | ₹42 Cr -14.7% | ₹49 Cr +45.9% | ₹33 Cr +27.9% | ₹26 Cr | |
| Net Profit | ₹243 Cr +210.8% | ₹78 Cr +145.6% | ₹32 Cr ↑ Recovery | (₹32 Cr) ↓ Decline | ₹61 Cr -58.6% | ₹146 Cr -6.4% | ₹156 Cr +42.6% | ₹110 Cr |
| Profit (Owners) | ₹243 Cr +210.8% | ₹78 Cr +145.6% | ₹32 Cr ↑ Recovery | (₹32 Cr) ↓ Decline | ₹61 Cr -59.0% | ₹148 Cr -5.4% | ₹156 Cr +39.1% | ₹112 Cr |
| Minority Interest | ₹0.00 Cr +100.0% | (₹0.00 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹3 Cr) |
| Other Comprehensive Income | ₹4 Cr ↑ Recovery | (₹2 Cr) +2.9% | (₹2 Cr) ↓ Decline | ₹3 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹0.27 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹0.43 Cr |
| EPS | ₹12.44 | ₹4.00 | ₹1.84 | (₹1.87) | ₹3.49 | ₹9.06 | ₹9.58 | ₹6.88 |
| Diluted Shares | ₹20 Cr | ₹20 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Profit Or Loss Of Associates | (₹1 Cr) +5.1% | (₹1 Cr) +74.0% | (₹5 Cr) +9.5% | (₹5 Cr) | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹2 Cr ↑ Recovery | (₹8 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Shilpa Medicare Limited has informed the Exchange about Schedule of meet
Shilpa Medicare Limited has informed the Exchange about Credit Rating
Shilpa Medicare Limited has informed the Exchange about the resignation of Dr. Sridevi Khambhampaty, as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a material subsidiary of Sh...
Shilpa Medicare Limited has informed the Exchange about Credit Rating
Shilpa Medicare Limited has informed the Exchange regarding a press release dated Jun 30, 2026, titled "Shilpa Biologicals Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare enters into a Co-develo...
Shilpa Medicare Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Shilpa Biocare Pvt Ltd, a Wholly owned Subsidiary of Shilpa Medicare and Gate2Brain Sign Strateg...
Shilpa Medicare Limited has informed the Exchange about USFDA Inspection at Unit VI, Dabaspet, Bengaluru
Shilpa Medicare Limited has informed the Exchange about Transcript
Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding Postal Ballot notice of the Company.
Shilpa Medicare Limited has informed the Exchange about Investor Presentation
Shilpa Medicare Limited has informed the Exchange regarding Notice of Postal Ballot
Shilpa Medicare Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 0.60 per equity share.
Shilpa Medicare Limited has submitted to the Exchange, Outcome of Board meeting held today, i.e., on 22 May 2026
Shilpa Medicare Limited has informed the Exchange about Schedule of meet
Appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO) Formulations (Senior Managerial Personnel)